COVID-19 Vaccines - Republic of the Congo

  • Republic of the Congo
  • The Republic of the Congo is expected to witness a significant surge in revenue within the COVID-19 Vaccines market.
  • By 2024, the projected revenue is estimated to reach US$9.56m.
  • This substantial revenue growth is anticipated to continue, with an annual growth rate (CAGR 2024-2029) of -17.84%.
  • As a result, the market volume is projected to reach US$3.58m by 2029.
  • When compared globally, it is noteworthy that United States is expected to generate the highest revenue in this market.
  • In 2024 alone, United States is projected to generate a revenue of US$4,389,000.00k.
  • The Republic of the Congo has seen a rise in demand for COVID-19 vaccines due to increasing public awareness and government efforts.

Key regions: United Kingdom, Germany, France, South Korea, Italy

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Republic of the Congo, also known as Congo-Brazzaville, is a country located in Central Africa. The COVID-19 pandemic has affected the country, and like many other countries, the government has implemented measures to contain the spread of the virus. In this context, the COVID-19 Vaccines market in the Republic of the Congo has been developing in a certain way.

Customer preferences:
As in many other countries, the population of the Republic of the Congo is concerned about the COVID-19 pandemic. People are looking for solutions to protect themselves and their families from the virus. The demand for vaccines is high, and people are willing to get vaccinated. However, there are concerns about the safety and efficacy of the vaccines, and the government and health authorities need to address these concerns to increase the vaccination rate.

Trends in the market:
The COVID-19 Vaccines market in the Republic of the Congo is still in its early stages. The government has received vaccines from different sources, including the COVAX initiative and China. The vaccination campaign started in April 2021, and the government aims to vaccinate 60% of the population by the end of 2022. However, the vaccination rate is still low, and there are challenges in reaching remote areas and convincing people to get vaccinated. The government and health authorities need to increase awareness about the benefits of vaccination and address concerns about the safety and efficacy of the vaccines.

Local special circumstances:
The Republic of the Congo has a population of around 5 million people, and the healthcare system is underfunded and understaffed. The country has also faced other health challenges, such as outbreaks of Ebola and yellow fever. The COVID-19 pandemic has put additional pressure on the healthcare system, and the government has had to allocate resources to contain the spread of the virus. The country also has a large informal sector, and many people work in the informal economy, which makes it difficult to implement measures such as lockdowns and social distancing.

Underlying macroeconomic factors:
The Republic of the Congo is a lower-middle-income country, and the economy is heavily dependent on oil exports. The COVID-19 pandemic has led to a decline in oil prices and a contraction of the economy. The government has had to implement austerity measures to address the budget deficit, and the healthcare system has been affected by the budget cuts. The government has received support from international organizations such as the World Bank and the International Monetary Fund to address the economic challenges and support the healthcare system.In conclusion, the COVID-19 Vaccines market in the Republic of the Congo is developing slowly, and the vaccination rate is still low. The government and health authorities need to increase awareness about the benefits of vaccination and address concerns about the safety and efficacy of the vaccines. The healthcare system is underfunded and understaffed, and the government needs to allocate resources to address the challenges posed by the pandemic. The economic challenges faced by the country also affect the healthcare system, and international support is needed to address the budget deficit and support the healthcare system.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)